伴有ALK融合致癌基因的转移性大细胞神经内分泌肺癌对阿来替尼部分缓解 - Suppr

Metastatic Large-Cell Neuroendocrine Lung Carcinoma With ALK Fusion Oncogene With Partial Response to Alectinib.

作者信息

Leblanc Andréanne, Owen Scott, Fiset Pierre Olivier, Gomez Corrador Andrea Liliam, Isenberg Jordan, Bouganim Nathaniel

机构信息

Department of Internal Medicine, McGill University, Montreal, QC, Canada.

Department of Oncology, McGill University, Montreal, QC, Canada.

出版信息

JCO Precis Oncol. 2021 Nov;5:802-807. doi: 10.1200/PO.20.00348.

DOI:10.1200/PO.20.00348

PMID:34994612

Abstract

摘要

相似文献

Metastatic Large-Cell Neuroendocrine Lung Carcinoma With ALK Fusion Oncogene With Partial Response to Alectinib.

JCO Precis Oncol. 2021 Nov;5:802-807. doi: 10.1200/PO.20.00348.

Large Cell Neuroendocrine Carcinoma Harboring an Anaplastic Lymphoma Kinase (ALK) Rearrangement with Response to Alectinib.

Intern Med. 2018 Mar 1;57(5):713-716. doi: 10.2169/internalmedicine.9368-17. Epub 2017 Nov 20.

[Alectinib and mixed large cell neuroendocrine carcinoma of the lung.].

Orv Hetil. 2023 Apr 9;164(14):548-554. doi: 10.1556/650.2023.32738.

Brigatinib vs alectinib in crizotinib-resistant advanced anaplastic lymphoma kinase-positive non-small-cell lung cancer (ALTA-3).

Future Oncol. 2021 Nov;17(32):4237-4247. doi: 10.2217/fon-2021-0608. Epub 2021 Aug 23.

Dramatic response to alectinib in a patient with ALK-rearranged squamous cell lung cancer.

Thorac Cancer. 2021 Sep;12(17):2420-2423. doi: 10.1111/1759-7714.14092. Epub 2021 Jul 29.

The use of alectinib in the first-line treatment of anaplastic lymphoma kinase-positive non-small-cell lung cancer.

Future Oncol. 2018 Aug;14(18):1875-1882. doi: 10.2217/fon-2018-0027. Epub 2018 Mar 14.

A Case of ALK-Rearranged Combined Lung Adenocarcinoma and Neuroendocrine Carcinoma with Diffuse Bone Metastasis and Partial Response to Alectinib.

Curr Oncol. 2022 Feb 3;29(2):848-852. doi: 10.3390/curroncol29020072.

Mixed responses to first-line alectinib in non-small cell lung cancer patients with rare ALK gene fusions: A case series and literature review.

J Cell Mol Med. 2021 Oct;25(19):9476-9481. doi: 10.1111/jcmm.16897. Epub 2021 Sep 19.

Next-Generation Sequencing Identified a Novel Crizotinib-Sensitive PLB1-ALK Rearrangement in Lung Large-Cell Neuroendocrine Carcinoma.

Clin Lung Cancer. 2021 May;22(3):e366-e370. doi: 10.1016/j.cllc.2020.05.026. Epub 2020 Jun 2.

A case of large-cell neuroendocrine carcinoma harboring an EML4-ALK rearrangement with resistance to the ALK inhibitor crizotinib.

J Thorac Oncol. 2014 Jun;9(6):e40-2. doi: 10.1097/JTO.0000000000000103.

引用本文的文献

Case report: Therapeutic response to lorlatinib in advanced large-cell neuroendocrine carcinoma of the lung and breast cancer: a heterochronous double malignancy perspective.

Front Pharmacol. 2024 Dec 10;15:1413897. doi: 10.3389/fphar.2024.1413897. eCollection 2024.

Dramatic Response to Ensartinib in Metastatic Neuroendocrine Tumors With a Novel CEP44-ALK Fusion: A Case Report and Literature Review.

Clin Respir J. 2024 Dec;18(12):e70040. doi: 10.1111/crj.70040.

A prognostic nomogram based on least absolute shrinkage and selection operator Cox regression in patients with pulmonary large-cell neuroendocrine carcinoma.

Transl Cancer Res. 2024 Feb 29;13(2):916-934. doi: 10.21037/tcr-23-1061. Epub 2024 Jan 24.

Two case reports: EML4-ALK rearrangement large cell neuroendocrine carcinoma and literature review.

Front Oncol. 2023 Nov 1;13:1227980. doi: 10.3389/fonc.2023.1227980. eCollection 2023.

Successful Treatment of ALK-Positive Large-Cell Neuroendocrine Carcinoma of the Lung With Sequential ALK Inhibitors: A Case Report.

JTO Clin Res Rep. 2023 Jun 15;4(7):100538. doi: 10.1016/j.jtocrr.2023.100538. eCollection 2023 Jul.

Response to selpercatinib in a patient with fusion-positive pulmonary large-cell neuroendocrine carcinoma: A case report.

Front Oncol. 2023 Mar 14;13:1134151. doi: 10.3389/fonc.2023.1134151. eCollection 2023.

Lorlatinib and compound mutations in ALK+ large-cell neuroendocrine lung carcinoma: a case report.

Cold Spring Harb Mol Case Stud. 2022 Oct 28;8(6). doi: 10.1101/mcs.a006234. Print 2022 Oct.

文献AI研究员

20分钟写一篇综述，助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型，支持多种主流文档格式。

立即体验

Metastatic Large-Cell Neuroendocrine Lung Carcinoma With ALK Fusion Oncogene With Partial Response to Alectinib.

作者信息

机构信息

出版信息

相似文献

引用本文的文献

文献AI研究员

用中文搜PubMed

文档翻译

Suppr 超能文献

Metastatic Large-Cell Neuroendocrine Lung Carcinoma With ALK Fusion Oncogene With Partial Response to Alectinib.

作者信息

机构信息

出版信息

相似文献

引用本文的文献